ELIZABETH PELLETIER: Open Payments
NPI 1114021482 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$655 in 32 payments from 16 companies in 2025. Trend: 2023 $1,176 · 2024 $908 · 2025 $655
Food & beverage: $655
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 12 | $215 |
| Janssen Scientific Affairs, LLC | 2 | $62 |
| TOLMAR, INC. | 2 | $54 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Janssen Biotech, Inc. | 2 | $40 |
| Boston Scientific Corporation | 2 | $38 |
| UROGEN PHARMA, INC. | 1 | $34 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $22 |
Products named: ORGOVYX, GEMTESA, ERLEADA, JATENZO, ADSTILADRIN, JELMYTO, LYNPARZA, OXLUMO.
Industry payments across MI — which companies pay providers there.
